The JUPITER-02 study (Fig. 1A) evaluated patients with nasopharyngeal carcinoma (NPC) randomized to toripalimab plus chemotherapy compared to placebo plus chemotherapy and retrospectively evaluated OS by PD-L1 status as defined by TPS ≥ 1% (n = 218) or TPS < 1% (n = 45). The gene discussed is CD274; the disease is nasopharyngeal carcinoma.